SNP_ID	Allele	Gene	Drug	Evidence_level	Efficacy	Dosage	Toxicity	Genotype	Description
rs8012552	C > T	BDKRB2	Ace Inhibitors, Plain	Level 3	-	-	decreased	TT	                Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of cough with ACE-inhibitors.
rs2108622	C > T	CYP4F2	acenocoumarol	Level 1B	-	increased	-	CT	                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.
rs1057910	A > C	CYP2C9	acenocoumarol	Level 2A	-	decreased	-	AC	                Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
rs2297480	T > G	FDPS	alendronate	Level 2B	decreased	-	-	GG	                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.
rs1056892	G > A	CBR3	anthracyclines and related substances	Level 2B	-	-	decreased	AA	                Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.
rs7997012	A > G	HTR2A	antidepressants	Level 2B	decreased	-	-	GG	                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.
rs3800373	C > A	FKBP5	antidepressants	Level 2B	decreased	-	-	AA	                Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.
rs1057910	A > C	CYP2C9	Antiinflammatory agents, non-steroids	Level 2A	-	-	increased	AC	                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.
rs1042522	C > G	TP53	antineoplastic agents	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1142345	T > C	TPMT	azathioprine	Level 1A	-	-	increased	CC	                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs2297480	T > G	FDPS	Bisphosphonates	Level 2B	decreased	-	-	GG	                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.
rs1057910	A > C	CYP2C9	celecoxib	Level 2A	-	-	increased	AC	                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.
rs1057910	A > C	CYP2C9	celecoxib	Level 2A	-	decreased	-	AC	                Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.
rs1142345	T > C	TPMT	cisplatin	Level 3	-	-	increased	CC	                Patients with the CC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.
rs1042522	C > G	TP53	cisplatin	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs9332377	C > T	COMT	cisplatin	Level 1B	-	-	increased	TT	                Patients with the TT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.
rs7997012	A > G	HTR2A	citalopram	Level 2B	decreased	-	-	GG	                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.
rs1042522	C > G	TP53	cyclophosphamide	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1057910	A > C	CYP2C9	diclofenac	Level 2A	-	-	increased	AC	                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.
rs11188072	C > T	CYP2C19	escitalopram	Level 3	-	increased	-	TT	                Patients with the TT genotype who are treated with escitalopram may require an increased dose  as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.
rs1042522	C > G	TP53	fluorouracil	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1057910	A > C	CYP2C9	losartan	Level 3	decreased	-	-	AC	                Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.
rs11188072	C > T	CYP2C19	mephenytoin	Level 3	-	increased	-	TT	                Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.
rs1142345	T > C	TPMT	mercaptopurine	Level 1A	-	-	increased	CC	                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs7997012	A > G	HTR2A	olanzapine	Level 3	-	-	decreased	GG	                Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.
rs11188072	C > T	CYP2C19	omeprazole	Level 2A	-	increased	-	TT	                Adult patients, but not pediatric patients, with the TT genotype who are treated with omeprazole may require an increased dose as compared to patients with the CT or CC genotype.  Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration. This might not be applicable to pediatric patients.
rs1042522	C > G	TP53	paclitaxel	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs11188072	C > T	CYP2C19	pantoprazole	Level 3	-	increased	-	TT	                Patients with the TT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.
rs2108622	C > T	CYP4F2	phenprocoumon	Level 1B	-	increased	-	CT	                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.
rs1057910	A > C	CYP2C9	phenytoin	Level 3	-	-	increased	AC	                Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.
rs1142345	T > C	TPMT	purine analogues	Level 1A	-	-	increased	CC	                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs2297480	T > G	FDPS	risedronate	Level 2B	decreased	-	-	GG	                Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patients chance of response.
rs1799978	T > C	DRD2	risperidone	Level 2A	decreased	-	-	CC	                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.
rs1799978	T > C	DRD2	risperidone	Level 3	-	-	increased	CC	                Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs7997012	A > G	HTR2A	Selective serotonin reuptake inhibitors	Level 2B	decreased	-	-	GG	                Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to antidepressants.
rs1142345	T > C	TPMT	thioguanine	Level 1A	-	-	increased	CC	                Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1057910	A > C	CYP2C9	valproic acid	Level 3	-	-	increased	AC	                Patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.
rs2108622	C > T	CYP4F2	warfarin	Level 1B	-	increased	-	CT	                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.
rs1057910	A > C	CYP2C9	warfarin	Level 1A	-	decreased	increased	AC	                Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.
